Attivare Therapeutics Secures Strategic Funding to Advance Next-Generation Immunotherapies and Malaria Vaccine
Attivare Therapeutics, a biotechnology company advancing novel immuno‑therapeutics using its proprietary ATTimmune biomaterial scaffold platform, has attracted a mix of strategic funding and grant capital that underscores broad confidence in its science and potential to transform both oncology and infectious disease prevention. The company, founded by a team from Harvard’s Wyss Institute for Biologically Inspired Engineering, has pursued an ambitious development path centered on harnessing biomaterials to recruit, reprogram and release immune cells in ways that enhance durability and efficacy of immune responses in diseases that have historically eluded effective treatment.
In December 2025, Attivare Therapeutics announced it had received a $6.6 million grant from the Gates Foundation to support the advancement of a next‑generation malaria vaccine built on its ATTimmune bioscaffold technology. This funding will advance work on long‑lasting vaccines capable of slow, controlled release of antigens and adjuvants, potentially reducing the need for frequent boosters while targeting underserved populations in low‑ and middle‑income countries where cold‑chain infrastructure limitations hinder vaccine coverage. Attivare’s approach aims to create robust, affordable and easily deployable solutions to one of the world’s most persistent infectious diseases, with malaria still responsible for significant morbidity and mortality among children in sub‑Saharan Africa and beyond.
The technical foundation for Attivare’s vaccine work and broader immunotherapy pipeline stems from biomaterial technologies originally developed at Harvard’s Wyss Institute and now licensed to Attivare. These mesoporous silica rod scaffolds form three‑dimensional immunomodulatory microenvironments that actively recruit and modulate immune cells in vivo, enabling sustained release of immunomodulatory agents and an enhanced response that can be tailored to both cancer and infectious disease applications.
Beyond grant support, Attivare has also secured venture backing in its early seed/pre‑A rounds from institutional investors that see value in its innovative platform. The biotech’s seed financing was led or co‑led by SymBiosis Capital Management, a venture capital firm focused on advancing biotherapeutics innovations. SymBiosis has supported Attivare’s work to translate breakthrough biomaterial science into practical therapeutics that can more effectively modulate immune responses in challenging disease contexts.
In addition to SymBiosis, other backers include Alebund and BiomX, both of which contribute to the company’s ability to build out its platform and advance multiple therapeutic programs toward clinical validation, helping bridge the gap between early scientific discovery and later-stage development.
The funding landscape for Attivare reflects a broader trend in biotech toward modular and engineered immunotherapies that go beyond conventional small molecules and biologics. By drawing on advanced biomaterial science and a platform capable of both recruiting and shaping immune responses, the company is positioning itself at the intersection of immuno-oncology and vaccine innovation. Its pipeline includes programs for cancer immunotherapy, such as ATT‑01 and ATT‑02, which leverage the ATTimmune platform to enhance innate immune activation and deliver immunomodulators like IL‑12 directly into tumor microenvironments. These programs have been featured in preclinical presentations at major scientific forums, signaling Attivare’s progress toward demonstrating platform value across multiple disease areas.
Leadership changes, including the appointment of Dr. David Sherris as President, CEO and Chairman, have strengthened Attivare’s operational capabilities as it scales its research and development efforts. With a seasoned executive at the helm and a pipeline that includes both cancer and vaccine candidates, the company is embarking on a development trajectory that could have significant implications for immunotherapy and global health.
The combination of non‑dilutive grant support and venture backing positions Attivare to pursue its strategic goals without compromising its scientific focus. The Gates Foundation grant in particular underscores the potential global impact of the firm’s malaria vaccine efforts, while investor confidence from SymBiosis and associated partners highlights belief in the broader utility of the ATTimmune platform.
As Attivare moves forward, the company plans to leverage its expanded funding to accelerate preclinical work, scale manufacturing processes, deepen collaborations with global research institutions and regulatory bodies, and position its immuno‑therapeutic candidates for future clinical evaluation. With a unique blend of platform technology and strategic investor support, Attivare Therapeutics is advancing toward a future where engineered immune modulation could transform how we treat cancer and prevent infectious disease on a global scale.
